Author

Andrew Garton

Observed institution: Ichnos Sciences (United States)

OpenAlex ID: A5085233235

First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

2024 · Hang Quach, Bradley Augustson, et al. · Blood · 15

Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

2022 · Sanjay R Mohan, Cristiana Costa Chase, et al. · Blood · 14

Dose Escalation of ISB 1342, a Novel CD38xCD3 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

2023 · Prashant Kapoor, Don A. Stevens, et al. · Blood · 12

Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM)—Dose escalation (DE) results.

2025 · Eben I. Lichtman, Amit Khot, et al. · Journal of Clinical Oncology · 11

Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

2023 · Dickran Kazandjian, Hang Quach, et al. · Blood · 7

A Phase 1, First-in-Human, Dose Escalation and Dose-Expansion Study of a BCMAxCD38xCD3 Targeting Trispecific Antibody ISB 2001 in Subjects with Relapsed/Refractory Multiple Myeloma

2023 · Hanlon Sia, Vinu Menon, et al. · Blood · 6

Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients

2026 · Vinu Chandralayam Ayyappa Menon, Tomomi Matsuura, et al. · Clinical Pharmacology & Therapeutics · 3

A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma

2022 · Hanlon Sia, Peter T. Tan, et al. · Blood · 3

TRIgnite- 1Study, Phase 1, First-in-Human Study of ISB 2001: A BCMAxCD38xCD3-Targeting Trispecific Antibody for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)—Dose Escalation (DE) Results

2025 · Hang Quach, Bradley Augustson, et al. · Clinical Lymphoma Myeloma & Leukemia · 2

Abstract 3694: Clinical validation of a quantitative systems pharmacology (QSP) model of ISB 2001 used for deriving first in human (FIH) dose and efficient phase 1 dose escalation design in relapsed refractory multiple myeloma (RRMM) patients

2025 · Vinu Menon, Beata Holkova, et al. · Cancer Research · 2

554 Pharmacokinetics (PK) and pharmacodynamics (PD) of ISB 2001, a BCMAxCD38xCD3 trispecific antibody, in TRIgnite-1, the first-in-human (FIH) phase 1 study in relapsed/refractory multiple myeloma (RRMM)

2025 · Andrew Garton, Vinu Menon, et al. · Regular and Young Investigator Award Abstracts · 1

Abstract CT147: Pharmacokinetics (PK) and pharmacodynamics (PD) of ISB 2001, a novel BCMAxCD38xCD3 trispecific antibody from the first-in-human (FIH) phase 1 study in relapsed/refractory multiple myeloma patients

2025 · Andrew Garton, Vinu Menon, et al. · Cancer Research · 1

Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma

2024 · Binod Dhakal, Hang Quach, et al. · Blood · 1

ISB 2001: Accelerating Patient Benefits through Quantitative Systems Pharmacology (QSP) Guided First-in-Human (FIH) Starting Dose Selection

2024 · Vinu Menon, Lida Pacaud, et al. · Blood

Works count: 14

Citation count: 78

H-index: 6

I10-index: 4